Now showing items 1-2 of 2
Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
(Wiley Subscription Services, Inc., A Wiley Company, 2006-06)
No abstract.
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
(Wiley Subscription Services, Inc., A Wiley Company, 2006-01)
The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 ...